Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W21 alcohol reduction app at $13M ARR with 150K+ paying customers; $17.4M Series B Goodwater 2022 with neuroscience-based CBT and community support competing with Monument for gray-area drinker digital behavior change.
Reframe (formerly Glucobit) is a San Francisco-based digital health platform — backed by Y Combinator (W21) — providing people seeking to quit or reduce alcohol consumption with a neuroscience-based mobile app that combines behavioral psychology, habit tracking, and community support, achieving $13 million in annual revenue with 150,000+ paying customers after 10x growth in 12 months and 3,000% growth in 6 months to become one of the top health apps on the App Store. Founded in 2018 by Ziyi Gao and Vedant Pradeep, Reframe raised $17.4 million in a Series B in January 2022 from Goodwater Capital, applying evidence-based alcohol reduction techniques (including CBT, mindfulness, and neuroscience education about alcohol's brain effects) to the 30 million Americans who want to drink less but don't seek traditional addiction treatment.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.